Cyclerion Therapeutics Collaborates with Medsteer to Advance Depression Treatment Program.
ByAinvest
Tuesday, Jan 6, 2026 3:38 pm ET1min read
CYCN--
Cyclerion Therapeutics (CYCN) has entered a collaboration with Medsteer to advance its CYC-126 program for treatment-resistant depression. The company plans to integrate FDA-cleared device components and strategic partnerships to launch a Phase 2 study by late 2026. Cyclerion operates in the biotechnology sector, focusing on soluble guanylate cyclase (sGC) pharmacology for serious and orphan diseases.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet